Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma

Autor: Kongzhi Zhang, Shiguang Chen, Wenchang Yu, Weifu Liu
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Adult
Diarrhea
Male
Cancer Research
medicine.medical_specialty
Carcinoma
Hepatocellular
Pyridines
Antineoplastic Agents
Gastroenterology
lcsh:RC254-282
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Internal medicine
Genetics
medicine
Carcinoma
Humans
Apatinib
Chemoembolization
Therapeutic
Adverse effect
Transcatheter arterial chemoembolization
Aged
Neoplasm Staging
Retrospective Studies
business.industry
Liver Neoplasms
Cancer
Middle Aged
medicine.disease
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Combined Modality Therapy
Survival Analysis
BCLC Stage
Treatment Outcome
Oncology
chemistry
030220 oncology & carcinogenesis
Hepatocellular carcinoma
Hypertension
030211 gastroenterology & hepatology
Female
BCLC Stage C Hepatocellular Carcinoma
business
Research Article
Zdroj: BMC Cancer, Vol 18, Iss 1, Pp 1-8 (2018)
BMC Cancer
ISSN: 1471-2407
Popis: Background Hepatocellular carcinoma (HCC) is a common cancer worldwide, with a poor prognosis. Most patients are diagnosed at advanced stages and are only eligible for palliative therapy. Therefore, this study aimed to evaluate the safety and efficacy of transcatheter arterial chemoembolization (TACE) combined with apatinib (TACE-apatinib) treatment and TACE-alone treatment for Barcelona Clinic Liver Cancer stage C HCC. Methods We retrospectively reviewed 80 consecutive patients with BCLC stage C HCC who received TACE-apatinib or TACE-alone as the initial treatment. We compared the clinical and laboratory outcomes, imaging findings at 1 and 3 months after TACE, tumor response, time to progression (TTP), overall survival (OS), and adverse events between both groups. Results The overall response rate was higher in the TACE-apatinib group than in the TACE-alone group at 1 and 3 months after treatment (66.7% vs 39.6%, respectively, P = 0.020; 45.8% vs 17.6%, respectively, P = 0.021). The median TTP and OS in the TACE-apatinib group were longer than those of the TACE-alone group (TTP: 6.3 months vs 3.5 months, respectively, P = 0.002; OS: 13.0 months vs 9.9 months, respectively, P = 0.041). Apatinib-associated side effects such as hypertension, hand-foot syndrome, oral ulcers, proteinuria, and diarrhea were more prevalent in the TACE-apatinib group than in TACE-alone group (P
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje